Pioneering Biotherapeutics: Driving Growth and Innovation

Q1 2026 Financial Highlights: A Robust Performance

Protalix BioTherapeutics marked a successful first quarter in 2026, largely due to a significant $25 million milestone payment received from Chiesi. This payment was a direct result of the European Commission's approval of a new, extended dosing regimen for El Fabrio. The company's cash reserves reached $51 million by quarter-end, providing a solid foundation for ongoing operations and future investments.

Strategic Vision for 2026: Revenue Projections and Market Expansion

The company reiterated its financial projections for 2026, anticipating total revenues to fall between $78 million and $83 million. This outlook is primarily fueled by expected strong sales from El Fabrio and the continued progress of the PRX115 Phase 2 clinical trial. Protalix is committed to capturing a substantial share of the global Fabry market, aiming for 15-20% by 2031, while also advancing its PRX115 program for uncontrolled gout.

Operational Review: Revenues, Expenses, and Clinical Progress

First-quarter revenues totaled $33.8 million, significantly bolstered by the Chiesi milestone. Research and Development expenses saw an increase to $5.4 million, mainly allocated to the PRX115 Phase 2 study, demonstrating the company's commitment to pipeline development. Despite increased R&D, Protalix maintained a healthy financial profile with no outstanding debt, underscoring its fiscal prudence.

Leadership's Confidence: Driving Long-Term Value

Management expressed strong confidence in the company's long-term growth prospects, attributing this to robust strategic partnerships and a promising pipeline. The new El Fabrio dosing regimen is expected to enhance patient access and market penetration in Europe, contributing significantly to revenue growth in the latter half of 2026. Protalix believes its current strategy will continue to generate substantial value for stakeholders.

Analyst Insights: El Fabrio's Market Trajectory and PRX115 Enrollment

During the earnings call, analysts probed into the expected revenue cadence from Chiesi for El Fabrio sales and the potential for upward revisions to the 2026 guidance. Management clarified that the impact of the new dosing regimen would likely be more apparent in the second half of the year, following country-specific reimbursement approvals. Regarding PRX115, the company confirmed that enrollment for the Phase 2 trial is progressing as planned, with top-line results anticipated in the second half of 2027.

Addressing Gout Treatment: PRX115's Role in a Changing Landscape

Discussions also touched upon the positioning of PRX115 within the evolving gout treatment landscape, particularly concerning new URAT1 inhibitors. Protalix's representative affirmed confidence in PRX115's relevance for the segment of patients with uncontrolled gout, suggesting that this niche market would remain significant, providing ample opportunity for treatments like Uricas.

Global Expansion of El Fabrio: Regulatory Updates and Future Milestones

An update on El Fabrio's global launch and regulatory efforts was provided. While early market uptake data for the new four-week dosing regimen was not yet available, the company indicated optimism based on Chiesi's internal assessments. Protalix is actively pursuing further regulatory approvals in various geographies, with several targets in the pipeline for the next 12 months, promising expanded patient access.

Pipeline Advancement: The Future of PRX119

Attention also turned to PRX119, with inquiries about its next developmental milestones. Protalix's leadership stated that the company is actively working to define the specific indications for PRX119's mechanism of action and plans to provide more detailed updates by the end of the current quarter. The goal is to outline expectations for the commencement of Phase 1 clinical trials, marking another step forward in the company's innovative pipeline.